Befovacimab Biosimilar - Research Grade

Human

TFPI

>1mg/ml

IgG2 - lambda

CHO Cells

Concizumab Biosimilar - Research Grade (ICH5447), Marstacimab Biosimilar - Research Grade (ICH5671)

https://www.imgt.org/mAb-DB/

ICH3002

P10646

Blue ice

This product is a research-grade biosimilar of befovacimab, supplied as an unconjugated, non-therapeutic analog of the originator antibody for research use only. It is not a clinical drug and is not intended for diagnostic or therapeutic application. Befovacimab (formerly BAY 1093884) is a fully human IgG2 monoclonal antibody directed against tissue factor pathway inhibitor (TFPI), the natural anticoagulant that restrains the tissue factor/FVIIa (extrinsic) initiation phase of coagulation. By neutralising TFPI, the antibody was designed to restore thrombin generation independently of the intrinsic pathway, and it was investigated as a subcutaneous non-factor prophylaxis for haemophilia A and B, with or without inhibitors. Built around the TFPI target rather than defined by a hybridoma clone, this analog reproduces the binding specificity of the originator and is intended as a reference tool for characterising TFPI biology, antibody-target interactions, and the anti-TFPI therapeutic mechanism in vitro. It is offered at research scale with low endotoxin, suitable as a binding standard, assay control, or comparator in biochemical and cell-based work. Each preparation is provided for functional laboratory investigation. Tissue factor pathway inhibitor (TFPI, UniProt P10646) is a Kunitz-type serine protease inhibitor and the principal endogenous regulator of the tissue factor-initiated coagulation cascade. Through its Kunitz-1 (K1) domain it binds and inhibits the TF/FVIIa complex, while its Kunitz-2 (K2) domain directly inhibits activated Factor X (FXa); a K3 domain and basic C-terminus support cofactor interactions such as with protein S. By dampening the extrinsic pathway, TFPI limits thrombin generation and helps maintain haemostatic balance. In haemophilia, where the intrinsic amplification loop is impaired, TFPI blockade is a rational strategy to rebalance coagulation. Befovacimab engages both the K1 and K2 domains, blocking TFPI inhibition of TF/FVIIa and FXa. TFPI biology is central to thrombosis, anticoagulation, and non-factor haemophilia therapeutics.

Extrinsic pathway inhibitor, EPI, Lipoprotein-associated coagulation inhibitor, LACI, Tissue factor pathway inhibitor, TFPI1

This monoclonal antibody was purified using Protein A

Sterile, preservative-free, solution in PBS. BSA and Azide free.

This biosimilar is stable when stored at 2-8°C. For longer term storage (> 3 months) it is recommended to store this antibody at -20°C or -70°C.

Functional Assays

This biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.

Products are for research use only. Not for use in diagnostic or therapeutic procedures.

3-4 weeks

Q: Is the Befovacimab biosimilar available in gram quantities?

A: Yes — it is manufactured in scalable milligram to gram quantities to support bulk and high-throughput preclinical experiments.

Q: Is this research-grade Befovacimab biosimilar suitable for in vivo studies?

A: Yes, it is supplied in a low-endotoxin, in vivo-ready formulation intended for preclinical and in vivo research use only (RUO).

Q: What does the Befovacimab biosimilar target?

A: It is an unconjugated, non-therapeutic research analog of Befovacimab that binds TFPI; for research use only.